Form 4: Apellis Pharmaceuticals Director A. Sinclair Dunlop Reports Stock and Option Transactions

Director A. Sinclair Dunlop reports acquisition of restricted stock units and stock options in Apellis Pharmaceuticals, along with indirect ownership through Epidarex.

Summary

• On January 1, 2025, A. Sinclair Dunlop, a director of Apellis Pharmaceuticals, acquired 6,267 shares of common stock through restricted stock units and 11,199 stock options.
• The restricted stock units vest fully on the first anniversary of the grant date, contingent upon continued service as a director.
• The stock options vest quarterly from the grant date and expire seven years after the grant date.
• Dunlop also has indirect ownership of 100,000 shares of common stock through Epidarex, where he is a general partner.
• He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
• Following these transactions, Dunlop directly owns 158,393 shares of common stock and indirectly owns 100,000 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of stock and options by a director signals confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Monitoring such filings can provide insights into management's sentiment and expectations regarding the company's performance.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment as it indicates the director's continued investment in the company.

Key Dates